[关键词]
[摘要]
足癣、股癣和体癣的发病率较高,又极易复发,严重影响到患者的生活质量。2013年11月,美国FDA批准1%卢立康唑乳膏上市,外用治疗趾间足癣、股癣和体癣。该药是一种新型咪唑类外用抗真菌药,具有抗菌谱广、抑菌作用强的特点。研究显示1%卢立康唑乳膏外用治疗足癣、股癣和体癣安全有效,尤其是治疗股癣和体癣时,仅需每日1次,治疗1周,与目前其他治疗药物(需要治疗2周)相比,疗程更短。
[Key word]
[Abstract]
The tinea pedis, tinea cruris, and tinea corporis can seriously affect the quality of life of patients due to high incidences and high recurrence rate. Luliconazole cream 1% was approved by the United States Food and Drug Administration (FDA) for the topical treatment of tinea pedis, tinea cruris and tinea corporis for external use in November 2013. Luliconazole is a novel broad-spectrum topical imidazole antifungal agent with potent antifungal effect. The studies have shown that luliconazole cream 1% is safe and effective in the treatment of tinea pedis, tinea cruris, and tinea corporis, especially for the two latter. The course of the treatment with luliconazole, once-daily for one week, is shorter than other existing drugs (usually for two weeks of treatment). This article reviews the pharmacodynamic studies and clinical evaluation for the treatment of fungal infections of luliconazole cream 1% and its development.
[中图分类号]
[基金项目]